In May 2011, BioAlliance signed a licensing deal with Sosei to carry out bridging development program and commercialization rights in Japan for Loramyc in the treatment of oropharyngeal candidiasis.
Sosei Group CEO Shinichi Tamura said, "We believe that the distribution agreement with FUJIFILM Pharma, which has expertise in infectious diseases, will help us expand the reach of Loramyc to more oropharyngeal candidiasis patients."
Following a Phase I clinical trial finalized in July 2012, Sosei had initiated a Phase III open-label trial in March 2013 which should be the final step before submission, as required by the Japanese authorities.
BioAlliance Pharma CEO Judith Greciet said the development plan of Loramyc in Japan is driven efficiently and in the timelines scheduled by company’s partner Sosei.
"Their partnership with FUJIFILM Pharma is implementing an optimized framework to start the commercialization of the product in Japan, one of the major markets in Asia," Greciet added.